(VIANEWS) – Shares of PCI BIOTECH HOLD (Oslo Børs All-share Index_GI: PCIB.OL) jumped by a staggering 17.32% to kr2.68 at 10:40 EST on Thursday, after three consecutive sessions in a row of losses. Oslo Børs All-share Index_GI is jumping 0.1% to kr1,414.92, after five sequential sessions in a row of losses. This seems, up to now, a somewhat bullish trend trading session today.
PCI BIOTECH HOLD’s last close was kr2.11, 64.68% below its 52-week high of kr5.96.
About PCI BIOTECH HOLD
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.937.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.59%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PCI BIOTECH HOLD’s stock is considered to be overbought (>=80).
Earnings Before Interest, Taxes, Depreciation, and Amortization
PCI BIOTECH HOLD’s EBITDA is 0.99.
Volatility
PCI BIOTECH HOLD’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.50%, a positive 0.92%, and a positive 7.04%.
PCI BIOTECH HOLD’s highest amplitude of average volatility was 4.50% (last week), 11.64% (last month), and 7.04% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.1%, now sitting on 4.75M for the twelve trailing months.
More news about PCI BIOTECH HOLD (PCIB.OL).
